SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to a potential short squeeze, fueled by its ultra-low float and high short interest; the community is actively discussing strategies to capitalize on the squeeze, while some caution against chasing the stock at its current levels. Comparisons to other low-float runners like HKD and PLRZ are rampant, with many anticipating a continued upward trajectory, while some users point to a lack of fundamentals.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as the community speculates about leaked news or upcoming hyperscaler deals, driving a notable pre-market surge. Community members are pointing to insider knowledge and potential for significant gains, while some caution against relying solely on speculation. The broader discussion involves the AI infrastructure market, with bullish investors emphasizing long-term growth potential and comparing APLD to other players in the data center space.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is trending due to a recently announced $1.5 billion public offering, causing immediate concern and discussion of potential dilution among shareholders. While some investors view this as a strategic move for growth and S&P 500 inclusion, others express distrust in management's handling of capital raises and worry about the stock's short-term performance. The community is actively debating the reasons behind the offering and its potential impact on the company's future.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Recent reports suggest Netflix is a leading contender in bidding for Warner Bros. Discovery's studio and streaming assets, sparking discussions about the potential deal's impact. The community is weighing the pros and cons of Netflix acquiring these assets, especially regarding debt implications and regulatory hurdles, while some believe this move will solidify Netflix's dominance in the streaming space.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Recent chatter around CRML is driven by discussions about a strategic copper powder stockpile acquisition and its implications for defense and advanced manufacturing. Community members are debating the value and potential impact of this move, as well as awaiting the BFS report, while also focusing on the broader context of rare earth mineral supply chains and government support.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies Inc. ($QCLS) is trending due to significant gains after American pharma investor Martin Shkreli announced a major investment, setting a bold price target, with community members actively discussing its potential in photonics and comparing it to other recent high runners. The community is buzzing about a potential short squeeze, the influence of Shkreli, and the long-term prospects of the company's technology.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics ($SNSE) is trending due to recent clinical trial results, which has sparked a debate about their potential and triggered significant volatility. The stock's low float is amplifying price swings, with community members discussing both potential for a short squeeze and risks associated with the company's financials and future capital needs. Traders are actively monitoring key price levels and comparing $SNSE's potential to previous high-flying stocks in the sector.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending due to a major outage impacting access to several online services and applications, sparking frustration within the community.  The incident has triggered discussions about the reliability of security companies and the increasing frequency of outages.  Despite the disruption, some analysts remain bullish, citing the company's growth potential and strategic position in edge computing and AI.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending as investors closely monitor its upcoming satellite launch, a key component of its post-quantum security infrastructure, with potential implications for securing data in the space and IoT sectors. Community discussions revolve around the company's innovative chip technology, its partnerships, and the timing of potential government contracts, while also weighing the risks of being a speculative small-cap. Talk about zero short shares and potential short squeeze.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BBAI is trending as investors discuss an upcoming meeting regarding share authorization, sparking debates about potential dilution. The community is analyzing the implications of Swiss National Bank's increased position in the company and discussing possible short squeeze scenarios. Bullish sentiment points to the defense and AI sectors as drivers, while bears express concerns about potential overvaluation and downside risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regencell Bioscience (NASDAQ:RGC) Trading 11.1% Higher - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Trading 11.1% Higher - Still a Buy...

Regencell Bioscience (NASDAQ:RGC) Stock Price Down 4.2% - What's Next?

Regencell Bioscience (NASDAQ:RGC) Shares Down 4.2% - Here's Why...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Should You Sell?

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Here's What Happened...

Regencell Bioscience (NASDAQ:RGC) Trading Up 10.5% - Time to Buy?

Regencell Bioscience (NASDAQ:RGC) Trading 10.5% Higher - Time to Buy...

<a href="https://stocktwits.com/symbol/RGC">Regencell Bioscience Holdings Ltd</a>. (RGC), a Hong Kong-based nano-cap biotech firm, has emerged as one of the most explosive stocks of 2025, skyrocketing 14,486% year-to-date.The staggering rally has captivated retail traders and propelled the stock into the top trending ranks of healthcare chatter on Stocktwits.Over the past three months, message volume surrounding RGC has surged by 17,600% on Stocktwits, while its follower count has jumped 156%, reflecting some of the most intense engagement seen among small-cap health care stocks.Sentiment has mostly remained bullish over the same period, though cracks of doubt have&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">emerged</a> as traders digest the stock’s rise despite no formal news or clear catalysts.<figure class="image"><img style="aspect-ratio:1322/1354;" src="https://news.stocktwits-cdn.com/RGC_YTD_chart_with_sentiment_meter_and_message_volume_as_of_May_29_png_6a489def8e.webp" alt="RGC YTD chart with sentiment meter and message volume as of May 29.png" width="1322" height="1354"><figcaption>RGC YTD chart with sentiment meter and message volume as of May 29. | source: Stocktwits</figcaption></figure>Many retail investors remain wary, with some warning of a looming correction."$RGC one of these days this dumps 99% in [a] single trading session," said one user.<stembedurl>https://stocktwits.com/ItSaulGoodMaan/message/616270456</stembedurl>"$RGC this went up 20,000 % in 3 months, if they didn’t just cure cancer, then this is a scam," said another.<stembedurl>https://stocktwits.com/Lard_ass_piggy/message/616269720</stembedurl>Hong Kong-based Regencell focuses on traditional Chinese medicine (TCM), developing formulas aimed at treating ADHD and autism spectrum disorder (ASD).Despite its mission, the company has yet to commercialize any treatments, apply for regulatory approvals, or secure patents.&nbsp;In its most recent annual filing in October, the firm disclosed net losses of $4.36 million for fiscal 2024 and noted it may “never be profitable.”Insider activity appears to be fueling much of the move. According to media reports, insiders control 81% of the float, limiting public liquidity and potentially amplifying volatility.As of June 30, 2024, Regencell reported $8 million in cash and short-term investments, which it believed was enough to cover expenses for at least the following 12 months. However, it said it will likely need “substantial additional financing” to continue operations.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regencell Biotech Stock's Mind-Blowing 14,400% YTD Rally Draws Frenzied Retail Interest

Many retail investors remain wary, with some warning of a looming correction in the absence of formal news or clear catalysts.

Equity

Many retail investors remain wary, with some warning of a looming correction in the absence of formal news or clear catalysts.


Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Regencell Bioscience Holdings Ltd. shares have been on a tear recently, more than tripling in value even before the first quarter of 2025 has ended. Retail traders, however, are not overly bullish about this stock.Hong Kong-based Regencell focuses on the research, development, and commercialization of traditional Chinese medicine, targeting neurocognitive disorders and degeneration, particularly attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD).According to several media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://finance.yahoo.com/news/insiders-regencell-bioscience-holdings-limited-120457560.html">reports</a>, the recent rally has been driven mainly by buying from insiders, who own 81% of the company.The stock’s&nbsp;surge also comes amid a broader rally in Chinese stocks, driven by hopes of economic stimulus from Xi Jinping’s government.Koyfin data shows that only three institutional investors have a combined stake of a little over $156,000 in the company.A Stocktwits poll gauging retail sentiment on Regencell showed that 52% of nearly 1,000 respondents opted to stay away from the stock as it was "too risky for me," while 31% suggested they were buying it now.&nbsp;Another 12% said they were selling and taking profits, while 5% claimed to have "caught the move early."<figure class="image"><img style="aspect-ratio:1316/654;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/RGC_Stocktwits_poll_results_png_e989704d45.webp" alt="RGC Stocktwits poll results .png" width="1316" height="654"><figcaption>RGC Stocktwits poll results</figcaption></figure>Over the past three months, Regencell's following on Stocktwits has grown by 48% while message volume has soared by 30,000%.One bullish user claimed they bought Regencell stock when it was less than half its last close.<stembedurl>https://stocktwits.com/CryptoSenderX/message/607994621</stembedurl>However, a skeptic argued that RGC actually moved up "on no news. I'm shorting and waiting for the rug pull."<stembedurl>https://stocktwits.com/SmoothD/message/608057630</stembedurl>Regencell has not generated revenue or a profit ever since it went public on the Nasdaq in July 2021.&nbsp;It has a low float of about 802,000 shares, making it a highly volatile stock.One Stocktwits user expressed strong skepticism, saying, "This reeks of a scam so bad. Hong Kong biotech with 12 full-time employees. Chinese medicine ancient herbs for ADHD. This will collapse."<stembedurl>https://stocktwits.com/jimmieB/message/608370796</stembedurl>According to Koyfin, no analysts currently cover the stock on Wall Street. The stock ended Monday 46% higher and jumped another 42% in after-hours trading.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regencell Bioscience Stock Is Up Over 260% This Year — Are Retail Traders Riding The Wave Or Watching From The Sidelines?

The Hong Kong-based company focuses on researching, developing, and commercializing traditional Chinese medicine, targeting neurocognitive disorders and degeneration.

12 titoli sanitari in movimento, sessione regolare del 22/03/2024

Titoli in rialzo
Il titolo IMAC Hldgs (NASDAQ:BACK) salito del 93,02% a 2,49 dollari durante la sessione regolare di venerd .
Il titolo Regencell Bioscience (NASDAQ:RGC) ha osservato un incremento...

12 acciones de salud en movimiento en la sesi n intrad a del 11/03/2024

Acciones al alza
Regencell Bioscience (NASDAQ:RGC) experimentaron un repunte del 130,88% para establecerse en los 10,39 d lares durante la sesi n del regular del lunes.
TC BioPharm (Holdings...

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Current Price	$14.86
Prev Close	$13.01
Open	$13.14
Dividend Yield	0.00%
50-Day Moving Average	$15.06
Beta	-0.16
Avg. Volume	132,902.16
PE Ratio	-2,222.22

52-Week High	$83.60
52-Week Low	$0.0928
Market Capitalization	$6.43B
EPS (Annual)	-$0.0072
Price to Book	1,627.67
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

RGC
Regencell Bioscience Holdings Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RGC News

RGCRegencell Bioscience Holdings Ltd